Clinical trial
Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00482495 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00482495 |
|---|---|
| Title | Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma |
| Official title | A Phase II Trial of Bevacizumab in Patients With Relapsed or Refractory Multiple Myeloma |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Biological, Genetic, Other |
| Interventions | bevacizumab, gene expression analysis, protein expression analysis, laboratory biomarker analysis |
| Enrollment | 42 |
| Start date | Apr 1, 2006 |
| Primary completion | Dec 1, 2006 |
| Completion | Nov 1, 2009 |
| First posted | Jun 5, 2007 |
| Last update posted | May 11, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: